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Summary Morbidity andmortality inmultiplemyeloma is often attributed to life-threatening
infections. A defect in humoral immunity has been proposed for the predisposition to bacterial
infections. Most of the infections are of bacterial origin, and the most serious are septicemia,
meningitis, and pneumonia. Thalidomide is a drug with pleiotropic effects. The immunomo-
dulatory effects of thalidomide are at least partially mediated through its ability to down-
regulate the pathogenic over-production of tumor necrosis factor-alpha (TNF-a). TNF-a is a
cytokine that plays a central role in the regulation of the host immune and inflammatory
response to infection. In the central nervous system, TNF-a is involved in induction of a fever
response and triggers the release of other cytokines, and may also influence transport of
compounds into the brain, leading to cerebrospinal fluid leukocytosis, increased protein influx,
and lactate accumulation. Thalidomide has been shown to down-regulate the production of TNF-
a. On the other hand, knowledge of the effects of thalidomide on granulocyte functions is
limited. Thalidomide has been shown to attenuate neutrophil adhesion and chemotaxis. We
present herein two cases of Streptococcus pneumoniaebacterialmeningitis that developed soon
after the initiation of thalidomide treatment, and discuss the effect of thalidomide on the
immune system. Although, it is not clear whether thalidomide caused the development of the
bacterial infections andmeningitis, or what its pathogenetic mechanisms are, physicians should* Corresponding author. Tel.: +90 412 2488233; fax: +90 412 2488440.
E-mail address: semirpasa@dicle.edu.tr (S. Pasa).
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be alert for signs and symptoms of meningitis in patients with multiple myeloma who are treated
with thalidomide, especially those in neutropenic states.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Morbidity and mortality in multiple myeloma is often attrib-
uted to life-threatening infections. A defect in humoral
immunity has been proposed for the predisposition to bac-
terial infections. There is a known association between
multiple myeloma and a wide range of infections. Most of
these are of bacterial origin, and the most serious are
septicemia, meningitis, and pneumonia. The mostly com-
monly found organisms are polysaccharide-encapsulated
bacteria, and there is a specific susceptibility to infection
with Streptococcus pneumoniae.1 It has been noted that
titers of anti-capsular polysaccharide antibodies to S. pneu-
moniae in non-vaccinated multiple myeloma patents are
below the 10th percentile of a normal adult cohort.2
Thalidomide is a drug with pleiotropic effects. The immu-
nomodulatory effects of thalidomide are at least partially
mediated through its ability to down-regulate the pathogenic
over-production of tumor necrosis factor-alpha (TNF-a).3
TNF-a is a cytokine that plays a central role in the regulation
of the host immune and inflammatory response to infection.4
Besides its protective role, TNF-a production has been asso-
ciated with the development of pathology, including tissue
necrosis. In the central nervous system (CNS), TNF-a is
involved in the induction of the fever response and triggers
the release of other cytokines, and may also influence trans-
port of compounds into the brain, leading to cerebrospinal
fluid (CSF) leukocytosis, increased protein influx, and lactate
accumulation. Thalidomide has been shown to down-regu-
late the production of TNF-a. Most studies on the mode of
action of thalidomide have focused on mononuclear cells.
However, granulocytes constitute a first line of defense to an
invading microorganism. Knowledge of the effects of thali-
domide on granulocyte functions is limited. Thalidomide has
been shown to attenuate neutrophil adhesion and chemo-
taxis.5,6
Herein we present two cases of bacterial meningitis that
developed soon after the initiation of thalidomide treat-
ment, and discuss the effect of thalidomide on the immune
system.
Case reports
Case 1
A 57-year-old male, who had been followed-up for a diagnosis
of multiple myeloma for 10 months, was admitted to our
emergency service with confusion and dysarthria. There
were no pathological signs on physical examination except
the alterations in his mental status. He had undergone four
cycles of VAD (vincristine, doxorubicin, and dexamethasone),
at which point (4 days prior to this admission) the treatment
had been changed to thalidomide (100 mg/day)—dexametha-
sone (40 mg/day), since he refused autologous transplanta-
tion. The patient’s mental status had altered progressivelywith the initiation of thalidomide. On laboratory examination
his urea was 28 mg/dl, creatinine was 0.8 mg/dl, total pro-
tein was 8.5 g/dl, albumin was 2.1 g/dl, globulin was 6.4 g/
dl, aspartate aminotransferase (AST) was 46 U/l, alanine
aminotransferase (ALT) was 81 U/l, alkaline phosphatase
(ALP) was 65 U/l, white blood cell (WBC) count was
2.71  109/l, neutrophil count was 1.09  109/l, hemoglobin
(Hb) was 10.2 g/dl, hematocrit was 30.6%, platelet count was
103  109/l, erythrocyte sedimentation rate (ESR) was 129/
h, b-2 microglobulin was 9.8 mg/l, and C-reactive protein
(CRP) was 89 mg/dl. Cranial computed tomography (CT) and
magnetic resonance imaging (MRI) were normal. The patient
was hospitalized and thalidomide treatment was interrupted
because of the suspicion of adverse effects, i.e., somno-
lence, which is very often observed. Lumbar puncture was
performed on the second day because of new-onset convul-
sions. Examination of the CSF revealed pleocytosis of
251  106 cells/l (8% mononuclear cells, 92% polymorpho-
nuclear cells) with an increased protein level of 216 mg/
dl. The CSF/serum glucose ratio was 0.32, and the culture of
a CSF sample was positive for S. pneumoniae. He was treated
successfully with ceftriaxone 4 g/day, and was followed for
11 days in our intensive care unit. The treatment for mye-
loma was changed to bortezomib after recovery of the
meningitis, and the patient is still on treatment with borte-
zomib.
Case 2
A 55-year-old male patient was admitted to our hematology
department with a history of irregular treatment of multiple
myeloma. He had undergone four cycles of VAD and then
thalidomide (200 mg/day), irregularly for about 6 months.
He did not come to his regular control visits, and did not
receive any specific treatment for the myeloma for 5 weeks.
On physical examination he had lumbar pain and anemia-
related signs and symptoms. On laboratory examination his
urea was 49 mg/dl, creatinine was 1.5 mg/dl, total protein
was 11.3 g/dl, albumin was 2 g/dl, globulin was 9.2 g/dl, AST
was 39 U/l, ALTwas 28 U/l, ALP was 165 U/l, WBC count was
2.49  109/l, neutrophil count was 0.697  109/l, Hb was
5.04 g/dl, hematocrit was 14.6%, platelet count was
65  109/l, ESR was 140/h, b-2 microglobulin was 11.6 mg/
l, and CRP was 152 mg/dl. After his initial evaluation, thali-
domide (100 mg/day)—dexamethasone (40 mg/day) was
startedagain, buthis vital signsandmental statuswerealtered
on the sixth day of the treatment. He was intubated and
referred to our intensive care unit for mechanical ventilation
because of loss of spontaneous breathing, and fever. A lumbar
puncture revealed pleocytosis of 459 106 cells/l (10%mono-
nuclear cells, 90% polymorphonuclear cells) with an increased
protein level of 124 mg/dl. The CSF/serum glucose ratio was
0.28, and the culture of a CSF sample was positive for S.
pneumoniae. He was treated successfully with appropriate
antibiotic therapy and is still under follow-up at our hematol-
ogy department.
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Thalidomide, a derivative of glutamic acid, was introduced in
Europe in 1954 as a sedative/hypnotic agent, but was
removed from the market when its teratogenic effects were
discovered. Thalidomide has been re-discovered as an anti-
inflammatory drug in the treatment of a wide range of
diseases, including mycobacterial infections, sarcoidosis,
Crohn’s disease, and AIDS-related ulcers.7
The immunomodulatory effects of thalidomide are at
least partially mediated through its ability to down-regulate
the pathogenic over-production of TNF-a. TNF-a is a cytokine
that has recently been determined to play a central role in
the regulation of the host immune and inflammatory
response to infection.3,4 Besides its protective role, TNF-a
production has been associated with the development of
pathology in vivo, including tissue necrosis and cachexia.
In the CNS, TNF-a is involved in the induction of a fever
response, activates the hypothalamus—pituitary—adrenal
axis, and triggers the release of other cytokines. TNF-a
may also influence the transport of compounds into the brain
and the local production of inflammatory cytokines, leading
to CSF leukocytosis, increased protein influx, and lactate
accumulation. In patients with bacterial meningitis, high
TNF-a levels in the CSF correlate with increased levels of
interleukin-6 and protein, as well as low glucose levels. In
addition, TNF-a and interleukin-1b levels are associated with
prolonged fever, seizures, spasticity, severity of disease,
clinical outcome, and death. Hence the control of inflamma-
tion even during antibiotic treatment of CNS infections is of
vital importance.5,6
Thalidomide has been shown to down-regulate the produc-
tion of TNF-a both in vivo and in vitro. Additionally, it has been
shown that in infected rabbits, inhibition of the TNF-a produc-
tion by thalidomide treatment may block the development of
meningitis.3—6 In contrast to these beneficial immunomodu-
latory effects, we observed two cases of newly developed
bacterial meningitis in patients who were treated with thali-
domide; however the main pathogenetic mechanisms and the
possible relation between thalidomide and the infections
remain unclear. Similarly, in a recently published study, Facon
et al.7 compared the results of melphalan and prednisone plus
thalidomide with melphalan and prednisone alone in elderly
patients with multiple myeloma, and two cases of bacterial
meningitis were reported as an emergent complication in the
patients who were treated with thalidomide.
Most studies on the mode of action of thalidomide have
focused on mononuclear cells. However, granulocytes con-
stitute a first line of defense to an invading microorganism.
Activation of granulocytes is associated with an up-regulation
of CD11b and a concurrent down-regulation of L-selectin.
Activation is further characterized by granulocyte degranu-
lation, resulting in the release of the granule products elas-
tase and lactoferrin. Knowledge of the effects of thalidomide
on granulocyte functions is limited. Treatment of human
umbilical vein endothelial cells with thalidomide resulted
in stimulation or inhibition of transmigration of neutrophils.
Thalidomide attenuated neutrophil chemotaxis in vitro but
did not influence respiratory burst activity.8
The blood—brain barrier (BBB) endothelium expresses
multiple leukocyte adhesion molecules and presents chemo-
tactic factors such as interleukin-8 when activated by inflam-matory mediators such as TNF-a, nitric oxide, and matrix
metalloproteinase-2. This combination promotes neutrophil
adherence and transendothelial migration. Inhibition of the
TNF-a with thalidomide may restore the BBB and result in
decreased permeability, but on the other hand it also causes
neutrophil adherence and chemotaxis to decrease.9 In addi-
tion to these deteriorated neutrophil functions caused by
thalidomide and the immunosuppressive state of the mye-
loma patients, the neutrophil count of our second case was
low. This low neutrophil count is probably a result of
advanced disease. It has been shown that thalidomide treat-
ment does not result in a change in leukocyte counts or
differentiation.8,10 The effect of thalidomide on decreasing
neutrophil functions in these advanced myeloma patients
may be more prominent.
From our literature review it would appear that this is the
first report of meningitis developing under thalidomide treat-
ment. Development of bacterial meningitis at the beginning
of thalidomide treatment, on the fourth and sixth day in our
cases, is not a chance occurrence; in a small-sized experi-
mental study, Juffermans et al.8 demonstrated that the
effect of thalidomide on deterioration of neutrophil func-
tions becomes evident after 3 hours and lasts at least
24 hours.
On the other hand, in these two presented cases and the
two cases of meningitis reported by Facon et al.,7 glucocor-
ticoids had also been used. Glucocorticoids affect virtually
every cell type involved in the immune and inflammatory
response, especially mononuclear cells and neutrophils. Glu-
cocorticoids decrease the secretion of interleukin-2, inter-
leukin-12, TNF-a, and interferon-g, and increase that of
interleukin-4, interleukin-5, and interleukin-10. Glucocorti-
coids also suppress several polymorphonuclear cell functions,
such as antibody-dependent cytotoxicity, adherence to vas-
cular endothelium, extravasation, phagocytosis, oxidative
burst and free radical generation, degranulation, nitric oxide
release, cytokine production, and chemotaxis. A>50% reduc-
tion in circulating lymphocytes has been reported 4 hours
after injection of 400 mg of hydrocortisone, which lasted for
24 hours. Monocytes are reduced by more than 40% after
administration of glucocorticoid, an effect that persists for
24 hours. This 400 mg hydrocortisone is equivalent to a dose
of 100 mg prednisone and 15 mg dexamethasone.11 Both the
two cases that are presented here and those reported by
Facon et al.7 were on treatment with higher doses of gluco-
corticoids for a long time. Therefore, the development of
meningitis may also be related to glucocorticoid usage.
However, the development of meningitis soon after admin-
istration of thalidomide is quite conspicuous. Additionally, it
has been shown that immunosuppression related to thalido-
mide therapy alone or in combination with prednisolone may
cause severe and disseminated viral and opportunistic infec-
tions.12,13
In conclusion, although it is not clear whether thalidomide
caused the development of the bacterial infections and
meningitis, or what its pathogenetic mechanisms are, phy-
sicians should be alert for signs and symptoms of meningitis in
patients with multiple myeloma who are treated with tha-
lidomide, especially those in neutropenic states. Lastly,
uncommon side effects of thalidomide such as bacterial
meningitis or other invasive infections should be confirmed
or not in meta-analyses.
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